Press Release Archives - Metrion Biosciences

Metrion Biosciences Appoints Dr Andrew Southan as Chief Executive Officer

Sophie Rose2019-04-08T08:01:46+00:00

Metrion Biosciences Appoints Dr Andrew Southan as Chief Executive Officer Cambridge, UK, 08 April 2019: Metrion Biosciences (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the appointment of Dr Andrew Southan as Chief Executive Officer, with immediate effect. Dr Southan was previously the Company’s Chief Operating Officer. Dr Southan joined [...]

Metrion Biosciences Appoints Dr Andrew Southan as Chief Executive OfficerSophie Rose2019-04-08T08:01:46+00:00

Metrion Biosciences closes funding round

Sophie Rose2019-04-01T08:22:36+00:00

Metrion Biosciences Closes Funding Round Includes investment from o2h Ventures Therapeutics Fund Funding to support expansion of ion channel screening capabilities and continued research into potential drugs for auto-immune diseases Cambridge, UK, 01 April 2019: Metrion Biosciences Ltd (“Metrion”), the specialist ion channel contract research and drug discovery company, announced today that it has completed [...]

Metrion Biosciences closes funding roundSophie Rose2019-04-01T08:22:36+00:00

Metrion Biosciences and LifeArc sign collaboration agreement

Andy Southan2019-03-01T15:13:12+00:00

Metrion Biosciences and LifeArc sign collaboration agreement for neuroscience-focused ion channel drug discovery Novel small molecule programme aims to address major unmet medical need in neuroscience Collaboration focused on specific potassium ion channel target Cambridge and London, UK, 29 January 2019: Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, and [...]

Metrion Biosciences and LifeArc sign collaboration agreementAndy Southan2019-03-01T15:13:12+00:00

Metrion Biosciences strengthens its drug discovery leadership team

Sophie Rose2019-03-01T15:16:28+00:00

Metrion Biosciences makes senior appointments to strengthen its drug discovery leadership team Dr Edward Stevens appointed as Head of Drug Discovery, and Dr Andrew Lightfoot as Head of Medicinal Chemistry and Discovery Funding Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced it has made two senior appointments [...]

Metrion Biosciences strengthens its drug discovery leadership teamSophie Rose2019-03-01T15:16:28+00:00

Metrion Biosciences and AMRI collaborate to offer ion channel drug discovery services

Andy Southan2018-09-10T14:38:27+00:00

Metrion Biosciences and AMRI collaborate to offer ion channel drug discovery services Agreement enables customers to access a broader range of drug discovery expertise. Metrion Biosciences Limited (“Metrion”), the specialist ion channel CRO and drug discovery company, and AMRI, a global contract research, development and manufacturing organization working with the life sciences industry to improve [...]

Metrion Biosciences and AMRI collaborate to offer ion channel drug discovery servicesAndy Southan2018-09-10T14:38:27+00:00

Metrion awarded £637k Innovate UK Biomedical Catalyst primer award

Sophie Rose2018-09-10T14:40:22+00:00

Metrion Biosciences awarded £637k funding under Innovate UK Biomedical Catalyst Primer Award for ion channel drug discovery • Funding will support project aiming to identify novel oral therapeutics for the auto-immune disease psoriasis • Adds to Innovate UK funding awarded in February 2018 for research on potassium channel inhibitors Cambridge, UK, 28 August 2018: Metrion [...]

Metrion awarded £637k Innovate UK Biomedical Catalyst primer awardSophie Rose2018-09-10T14:40:22+00:00

Metrion appoints two new Board Directors

Andy Southan2018-08-01T14:30:28+00:00

Dr Barry Kenny joins as Non-Executive Director Dr Andrew Southan, COO, appointed Executive Director Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced it has appointed Dr Barry Kenny and Dr Andrew Southan to its Board of Directors. The appointments have been made to strengthen the Company’s focus [...]

Metrion appoints two new Board DirectorsAndy Southan2018-08-01T14:30:28+00:00

Metrion Biosciences establishes Scientific Advisory Board

Andy Southan2018-11-26T15:28:23+00:00

Scientific Advisory Board will provide scientific oversight and strategic advice to support Metrion’s ion channel screening, cardiac safety testing, and native tissue and human stem cell translational assays. Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced that it has established a Science Advisory Board (SAB) to provide [...]

Metrion Biosciences establishes Scientific Advisory BoardAndy Southan2018-11-26T15:28:23+00:00

Innovate UK Biomedical Catalyst Feasibility Award

Metrion2018-07-18T16:02:11+00:00

Metrion Biosciences awarded £200k funding under Innovate UK Biomedical Catalyst Feasibility Award Funding will support further development of recently acquired small molecule assets for treatment of autoimmune disease Project forms the first of a series designed to deliver proof of concept data on immune-sparing drug candidates Project will further enhance Metrion’s ion channel drug discovery [...]

Innovate UK Biomedical Catalyst Feasibility AwardMetrion2018-07-18T16:02:11+00:00

Novel potassium channel inhibitors acquired from Japan Tobacco Inc.

Andy Southan2018-04-13T13:35:54+00:00

Acquired intellectual property rights have potential application in a variety of clinical indications, including auto-immune disorders and neurodegenerative diseases. Metrion now owns all patented and unpatented IP developed during previous collaboration between Metrion and Japan Tobacco Inc. Cambridge, UK, 29 January 2018: Metrion Biosciences Ltd (“Metrion”), the specialist ion channel contract research and drug discovery [...]

Novel potassium channel inhibitors acquired from Japan Tobacco Inc.Andy Southan2018-04-13T13:35:54+00:00